| 1 |
34609036 | Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B0 -shim array coils at 3 T. | 2022 Jan |
2 |
| 2 |
34941573 | Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment. | 2022 Feb 8 |
1 |
| 3 |
34985589 | Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment. | 2022 Feb |
2 |
| 4 |
34994387 | IDH Mutated Gliomas Promote Epileptogenesis through D-2-Hydroxyglutarate Dependent mTOR Hyperactivation. | 2022 Jan 5 |
1 |
| 5 |
35104795 | Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. | 2022 Feb |
4 |
| 6 |
35157758 | Distinct metabolic hallmarks of WHO classified adult glioma subtypes. | 2022 Feb 14 |
1 |
| 7 |
35198955 | The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. | 2022 |
2 |
| 8 |
35267433 | Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. | 2022 Feb 22 |
4 |
| 9 |
35314408 | Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma. | 2022 Jun |
2 |
| 10 |
35353219 | A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. | 2022 Mar 30 |
4 |
| 11 |
35493690 | Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. | 2022 Jun |
10 |
| 12 |
35606087 | Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. | 2022 May |
2 |
| 13 |
32940938 | Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study. | 2021 Feb |
1 |
| 14 |
33043739 | Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. | 2021 Feb |
1 |
| 15 |
33244787 | The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. | 2021 May |
2 |
| 16 |
33360716 | Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers. | 2021 Apr |
2 |
| 17 |
33523209 | Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration. | 2021 Jul 7 |
2 |
| 18 |
33632416 | Magnetic resonance spectroscopy for the study of cns malignancies. | 2021 Feb |
2 |
| 19 |
33668509 | Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. | 2021 Feb 13 |
2 |
| 20 |
33709779 | Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. | 2021 Jun |
1 |
| 21 |
33808599 | The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. | 2021 Mar 19 |
1 |
| 22 |
33811494 | The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy. | 2021 Nov |
3 |
| 23 |
33832922 | Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. | 2021 Apr |
2 |
| 24 |
33894275 | In cancer, all roads lead to NADPH. | 2021 Oct |
1 |
| 25 |
33981605 | Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. | 2021 |
2 |
| 26 |
34065652 | Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics. | 2021 May 16 |
2 |
| 27 |
34069550 | A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. | 2021 May 19 |
2 |
| 28 |
34095989 | IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. | 2021 Jul |
2 |
| 29 |
34170697 | Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant. | 2021 Jul 8 |
1 |
| 30 |
34224582 | Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma. | 2021 Dec 15 |
4 |
| 31 |
34289383 | Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. | 2021 Sep 16 |
2 |
| 32 |
34321251 | Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. | 2021 Oct |
4 |
| 33 |
34516556 | Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1α axis. | 2021 |
3 |
| 34 |
34531086 | Prognostic impact of IDH mutations in chondrosarcoma. | 2021 Sep 13 |
4 |
| 35 |
34535560 | Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. | 2021 Dec |
3 |
| 36 |
34557149 | Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T. | 2021 |
1 |
| 37 |
34571995 | D-2-Hydroxyglutarate in Glioma Biology. | 2021 Sep 7 |
3 |
| 38 |
34610989 | Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas. | 2021 Nov 23 |
4 |
| 39 |
34632051 | R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway. | 2021 Dec 17 |
2 |
| 40 |
34725432 | Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. | 2021 Nov 1 |
1 |
| 41 |
34829476 | Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of "False-Positive" Cases. | 2021 Nov 16 |
1 |
| 42 |
31028664 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. | 2020 Apr |
1 |
| 43 |
31485826 | To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma. | 2020 Jan |
1 |
| 44 |
31505989 | Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells. | 2020 Mar |
2 |
| 45 |
31526886 | Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics. | 2020 Jan |
1 |
| 46 |
31586149 | In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. | 2020 Feb |
2 |
| 47 |
31609487 | Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma. | 2020 Apr |
8 |
| 48 |
31650436 | In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. | 2020 Feb |
1 |
| 49 |
31727689 | A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model. | 2020 Feb |
4 |
| 50 |
31841594 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. | 2020 Feb 13 |
2 |